Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Curr Radiopharm ; 16(1): 2-22, 2023.
Article in English | MEDLINE | ID: mdl-35538822

ABSTRACT

Targeted Alpha Therapy (TAT) is considered an evolving therapeutic option for cancer cells, in which a carrier molecule labeling with an α-emitter radionuclide make the bond with a specific functional or molecular target. α-particles with high Linear Energy Transfer (LET) own an increased Relative Biological Effectiveness (RBE) over common ß-emitting radionuclides. Normal tissue toxicity due to non-specific uptake of mother and daughter α-emitter radionuclides seems to be the main conflict in clinical applications. The present survey reviews the available preclinical and clinical studies investigating healthy tissue toxicity of the applicable α -emitters and particular strategies proposed for optimizing targeted alpha therapy success in cancer patients.


Subject(s)
Neoplasms , Radiopharmaceuticals , Humans , Radiopharmaceuticals/pharmacology , Radiopharmaceuticals/therapeutic use , Radioisotopes/therapeutic use , Neoplasms/drug therapy , Alpha Particles/therapeutic use
2.
Curr Radiopharm ; 15(2): 134-140, 2022.
Article in English | MEDLINE | ID: mdl-34488603

ABSTRACT

BACKGROUND: The testis is one of the most radiosensitive tissues in pelvic radiotherapy, especially in prostate cancer. Febuxostat (FBX), as an inhibitor of xanthine oxidase, has anti-inflammatory, antioxidant, and anti-apoptosis properties. OBJECTIVES: The aim of this research was to survey the protective effect of FBX against irradiation (IR)-induced testis damage via the attenuation of oxidative stress. METHODS: Male adult mice were randomly assigned into eight groups: control, FBX with three doses of 5, 10, and 15 mg/kg, IR with 6 Gy, IR + FBX (IR + FBX in three doses), respectively. In the IR + FBX groups, FBX was administrated for 8 consecutive days, and then mice were exposed to IR at a dose of 6 Gy on the 9th day. One day after irradiation, biochemical parameters were evaluated in the testis of animals, while histopathological assessment had been performed on 14th day. RESULTS: Irradiation led to the induction of testicular toxicity. FBX significantly protected histopathological alterations and decreased oxidative stress parameters in irradiated testis. Besides, FBX increased the diameter and germinal epithelial thickness of seminiferous tubules and Johnson's score in irradiated mice. CONCLUSION: Data showed that FBX markedly protected testicular injury induced by IR by inhibiting oxidative stress and may be considered as an infertility inhibitor in cancer patients, especially prostate cancer.


Subject(s)
Prostatic Neoplasms , Radiation-Protective Agents , Animals , Febuxostat/pharmacology , Humans , Male , Mice , Prostatic Neoplasms/drug therapy , Radiation, Ionizing , Radiation-Protective Agents/pharmacology , Radiation-Protective Agents/therapeutic use , Radiopharmaceuticals/pharmacology , Testis/pathology , Testis/radiation effects
3.
Drug Chem Toxicol ; 45(6): 2586-2593, 2022 Nov.
Article in English | MEDLINE | ID: mdl-34538151

ABSTRACT

Febuxostat (FBX), a selective inhibitor of xanthine oxidase, has several biological properties such as antioxidant, anti-inflammatory and anti-apoptosis activities. The purpose of this study was to evaluate the protective effect of FBX against ionizing radiation (IR)-induced lung injury through mitigation of oxidative stress, inflammation and apoptosis. Sixty-four mice were randomized into eight groups as control, FBX (5, 10, and 15 mg/kg), IR (6 Gy), and IR + FBX (IR + FBX in three doses). Mice were received FBX for 8 consecutive days and then were exposed to IR at a single dose (6 Gy) of X-ray. At 1 and 7 days after irradiation, the biochemical parameters were analyzed in lung tissue, while histological and immunohistochemical examinations were evaluated 1 week after irradiation. Irradiation led to elevate of oxidative stress parameters (an increase of MDA, PC, NO, and decrease of GSH), inflammation and apoptosis in lung of mice. Furthermore, IR resulted in histopathological changes in the lung tissues. These changes were significantly mitigated by FBX treatment. FBX also inhibited immunoreactivity of caspase-3, NF-κB, and reduced oxidative stress. This study showed that FBX is able to protect lung injury induced by IR through inhibiting apoptosis (caspase-3), oxidative stress and inflammation (NF-κB).


Subject(s)
Febuxostat , Lung Injury , Animals , Mice , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Caspase 3 , Febuxostat/pharmacology , Febuxostat/therapeutic use , Inflammation/drug therapy , Lung Injury/drug therapy , Lung Injury/etiology , Lung Injury/prevention & control , NF-kappa B , Oxidative Stress , Radiation, Ionizing , Xanthine Oxidase/metabolism , Xanthine Oxidase/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...